Please assess the completion status of the following clinical trial:

Trial Title: A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants 18 to 80 years of age~* Participants should be qualified for inclusion based upon estimated CrCl ranges for normal renal function group and mild, moderate, and severe renal impairment groups~Exclusion Criteria:~* Participants with acute renal disease and/or history of renal transplant~* Urinary incontinence without catheterization~* Participants requiring hemodialysis~* Participants with LDL-C \<60 mg/deciliter (dL) (or less than 1.55 millimoles/liter \[mmol/L\])~* Participants with Amyloid Kidney (if known by pathology)~* Participants with any significant hepatic, cardiac, or pulmonary disease or participants who are clinically nephritic~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Inclisiran (normal renal function) (Type: EXPERIMENTAL): Participants will receive a single dose of 300 milligram (mg) inclisiran administered by SC injection on Day 1. Normal renal function is defined as estimated creatinine clearance (CrCl) of ≥90 milliliter (mL)/minute (min).
- Inclisiran (mild renal impairment) (Type: EXPERIMENTAL): Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Mild renal impairment is defined as CrCl ranging from 60 to 89 mL/min.
- Inclisiran (moderate renal impairment) (Type: EXPERIMENTAL): Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Moderate renal impairment is defined as CrCl ranging from 30 to 59 mL/min.
- Inclisiran (severe renal impairment) (Type: EXPERIMENTAL): Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Severe renal impairment is defined as CrCl ranging from 15 to 29 mL/min.

Based on this trial design, predict the completion outcome and termination type (if applicable).